CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
AffiliationUniversity of Liverpool, Royal Liverpool University hospital, University of Cardiff
MetadataShow full item record
AbstractKey Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.
CitationLucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K. & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood advances, 2(9), 964-8.
PublisherAmerican Society for Hematology
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/